Data from olaparib treated patients across histologies presented at Danske Kræftforskningsdage 2023

A Post-hoc exploratory analysis was presented at a poster session at “Danske Kræftforskningsdage 2023" by PhD student Maj Kamille Kjeldsen, showing that patients who had never received platinum containing chemotherapy had a significantly longer progression-free survival (PFS) compared to prior platinum exposed patients.

In the Phase 1 Unit at Rigshospitalet, 41 patients with 18 different cancer diagnosis have been treated with the PARP inhibitor olaparib between 2015 and 2022 based on extensive genomic profiling revealing genomic alterations indicative of homologues recombination deficiency (HRD), i.e., pathogenic alterations within homologous recombination repair (HRR) genes (BRCA1, BRCA2, ATM, CHEK2, etc.) and/or chromosomal changes known to arise from impaired homologues recombination (HR). , All 41 patients' SNP arrays were run via a newly implemented, laboratory developed, HRD script resulting in an HRD score: a combination score of three independent chromosomal characteristics (LOH, NtAIs and LSTs)1. Neither HRD score or mutations in HRR genes separated the treated patients with regards to PFS.

Danske Kræftforskningsdage (Danish Cancer Research Days) is a recurrent multi-disciplinary event bringing together health care professionals, patient advocates and political stakeholders for disseminating research, exchanging ideas and networking. Read more about the event here.

Link to presented poster

1: Marquard, A.M., Eklund, A.C., Joshi, T. et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 3, 9 (2015).

Responsible editor